Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
69.71
-0.19 (-0.27%)
Nov 4, 2024, 4:00 PM EST - Market closed
Belite Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
2.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLTE News
- 1 day ago - Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 3 months ago - Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan - GlobeNewsWire
- 6 months ago - Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript - Seeking Alpha